Is Xenetic Biosciences Stock a Good Investment?
Xenetic Biosciences Investment Advice | XBIO |
- Examine Xenetic Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Xenetic Biosciences' leadership team and their track record. Good management can help Xenetic Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Xenetic Biosciences' business and its evolving consumer preferences.
- Compare Xenetic Biosciences' performance and market position to its competitors. Analyze how Xenetic Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Xenetic Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Xenetic Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Xenetic Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Xenetic Biosciences is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Xenetic Biosciences Stock
Researching Xenetic Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 19.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.87. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Xenetic Biosciences recorded a loss per share of 2.66. The entity last dividend was issued on the 25th of June 2019. The firm had 1:10 split on the 15th of May 2023.
To determine if Xenetic Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Xenetic Biosciences' research are outlined below:
| Xenetic Biosciences had very high historical volatility over the last 90 days | |
| Xenetic Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.54 M. Net Loss for the year was (4.13 M) with profit before overhead, payroll, taxes, and interest of 1.16 M. | |
| Xenetic Biosciences currently holds about 14.93 M in cash with (4.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Roughly 19.0% of the company outstanding shares are owned by insiders | |
| Latest headline from finance.yahoo.com: Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis |
Xenetic Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Xenetic Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Xenetic Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Xenetic Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Xenetic Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-22 | 2022-12-31 | -0.09 | -0.1 | -0.01 | 11 | ||
2021-05-11 | 2021-03-31 | -0.13 | -0.15 | -0.02 | 15 | ||
2021-08-12 | 2021-06-30 | -0.16 | -0.13 | 0.03 | 18 | ||
2021-03-16 | 2020-12-31 | -0.2 | -0.16 | 0.04 | 20 | ||
2022-08-11 | 2022-06-30 | -0.12 | -0.19 | -0.07 | 58 | ||
2020-08-12 | 2020-06-30 | -0.22 | -0.15 | 0.07 | 31 | ||
2024-03-21 | 2023-12-31 | -0.87 | -0.77 | 0.1 | 11 | ||
2022-11-09 | 2022-09-30 | -0.18 | -0.06 | 0.12 | 66 |
Know Xenetic Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Xenetic Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Xenetic Biosciences backward and forwards among themselves. Xenetic Biosciences' institutional investor refers to the entity that pools money to purchase Xenetic Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sachetta Llc | 2024-09-30 | 17.4 K | Renaissance Technologies Corp | 2024-09-30 | 15.8 K | Geode Capital Management, Llc | 2024-06-30 | 12 K | Jtc Employer Solutions Trustee Ltd | 2024-09-30 | 2.7 K | Ubs Group Ag | 2024-06-30 | 182 | Bank Of America Corp | 2024-06-30 | 11.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 0.0 |
Xenetic Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.19 M.Market Cap |
|
Xenetic Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (0.42) | (0.44) |
Determining Xenetic Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Xenetic Biosciences is a good buy. For example, gross profit margin measures Xenetic Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Xenetic Biosciences' profitability and make more informed investment decisions.
Evaluate Xenetic Biosciences' management efficiency
Xenetic Biosciences has return on total asset (ROA) of (0.2874) % which means that it has lost $0.2874 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4861) %, meaning that it created substantial loss on money invested by shareholders. Xenetic Biosciences' management efficiency ratios could be used to measure how well Xenetic Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.41. In addition to that, Return On Capital Employed is likely to drop to -0.48. At this time, Xenetic Biosciences' Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 617.8 K, while Non Current Assets Total are likely to drop about 967.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.41 | 6.09 | |
| Tangible Book Value Per Share | 6.41 | 6.09 | |
| Enterprise Value Over EBITDA | 0.82 | 0.86 | |
| Price Book Value Ratio | 0.54 | 0.50 | |
| Enterprise Value Multiple | 0.82 | 0.86 | |
| Price Fair Value | 0.54 | 0.50 | |
| Enterprise Value | -3.7 M | -3.5 M |
The operational strategies employed by Xenetic Biosciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 2.263 |
Basic technical analysis of Xenetic Stock
As of the 22nd of November, Xenetic Biosciences maintains the Market Risk Adjusted Performance of 0.4371, downside deviation of 4.64, and Mean Deviation of 3.88. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Xenetic Biosciences, as well as the relationship between them.Xenetic Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xenetic Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xenetic Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xenetic Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Xenetic Biosciences' Outstanding Corporate Bonds
Xenetic Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Xenetic Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Xenetic bonds can be classified according to their maturity, which is the date when Xenetic Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand Xenetic Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Xenetic Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0233 | |||
| Market Risk Adjusted Performance | 0.4371 | |||
| Mean Deviation | 3.88 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 4.64 | |||
| Coefficient Of Variation | 5140.53 | |||
| Standard Deviation | 5.05 | |||
| Variance | 25.48 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0677 | |||
| Total Risk Alpha | (0.57) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.4271 | |||
| Maximum Drawdown | 26.99 | |||
| Value At Risk | (7.27) | |||
| Potential Upside | 7.65 | |||
| Downside Variance | 21.54 | |||
| Semi Variance | 20.24 | |||
| Expected Short fall | (4.52) | |||
| Skewness | 0.3501 | |||
| Kurtosis | 0.8706 |
| Risk Adjusted Performance | 0.0233 | |||
| Market Risk Adjusted Performance | 0.4371 | |||
| Mean Deviation | 3.88 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 4.64 | |||
| Coefficient Of Variation | 5140.53 | |||
| Standard Deviation | 5.05 | |||
| Variance | 25.48 | |||
| Information Ratio | (0) | |||
| Jensen Alpha | 0.0677 | |||
| Total Risk Alpha | (0.57) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.4271 | |||
| Maximum Drawdown | 26.99 | |||
| Value At Risk | (7.27) | |||
| Potential Upside | 7.65 | |||
| Downside Variance | 21.54 | |||
| Semi Variance | 20.24 | |||
| Expected Short fall | (4.52) | |||
| Skewness | 0.3501 | |||
| Kurtosis | 0.8706 |
Consider Xenetic Biosciences' intraday indicators
Xenetic Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Xenetic Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Xenetic Biosciences Corporate Filings
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify | |
| 21st of October 2024 Other Reports | ViewVerify |
Xenetic Stock media impact
Far too much social signal, news, headlines, and media speculation about Xenetic Biosciences that are available to investors today. That information is available publicly through Xenetic media outlets and privately through word of mouth or via Xenetic internal channels. However, regardless of the origin, that massive amount of Xenetic data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Xenetic Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Xenetic Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Xenetic Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Xenetic Biosciences alpha.
Xenetic Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Xenetic Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Xenetic Biosciences Corporate Executives
Elected by the shareholders, the Xenetic Biosciences' board of directors comprises two types of representatives: Xenetic Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenetic. The board's role is to monitor Xenetic Biosciences' management team and ensure that shareholders' interests are well served. Xenetic Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenetic Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Parslow | CFO, Principal Accounting Officer, Principal Financial Officer | Profile |
Already Invested in Xenetic Biosciences?
The danger of trading Xenetic Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xenetic Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xenetic Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xenetic Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Xenetic Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xenetic Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xenetic Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xenetic Biosciences Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Xenetic Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.